Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 10, Issue 10, 2001, Pages 1047-1053

  Decensi, Andrea ^a   Gonzaga, Aliana Guerrieri ^a   Diani, Silvia ^a   Johansson, Harriet ^a   Sandri, Maria T ^a   Miceli, Rosalba ^b   Mariani, Luigi ^b   Camerini, Tiziana ^b   Formelli, Franca ^b   Cavadini, Elena ^b   Di Mauro, Maria Gaetana ^b   De Palo, Giuseppe ^b   Barreca, Antonina ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; FENRETINIDE; RETINOIC ACID DERIVATIVE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECT; DRUG RECEPTOR BINDING; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG ADMINISTRATION SCHEDULE; FEMALE; FENRETINIDE; FOLLOW-UP STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONG-TERM CARE; MIDDLE AGED; NEOPLASM STAGING; REFERENCE VALUES; TREATMENT OUTCOME; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0034787931     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Insulin-like growth factor physiology and cancer risk
2. Role of the insulin-like growth factor family in cancer development and progression
3. The insulin-like growth factor-binding protein (IGFBP) superfamily
4. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
5. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
6. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
7. A prospective study of plasma insulin-like growth factor-I and binding protein-3 and risk of colorectal neoplasia in women
8. Serum insulin-like growth factor-I and breast cancer
9. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients
10. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients
11. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
12. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines
13. Surrogate endpoints in clinical trials: Definition and operational criteria
14. Plasma retinol level reduction by the synthetic retinoid fenretinide: A one year follow-up study of breast cancer patients
15. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: A comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum
16. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-I, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients
17. Analysis of longitudinal data
18. Growth hormone treatment induces mammary gland hyperplasia in aging primates
19. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density
20. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women
21. The endocrinology of aging
22. Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: Relation to age and sex steroid levels
23. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy
24. Serum insulin-like growth factor I in a random population sample of men and women: Relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin
25. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women
26. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study
27. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone
28. 9-cis Retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein
29. Estradiol induction of retinoic acid receptors in human breast cancer cells
30. 3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms
31. A decade of molecular biology of retinoic acid receptors
32. Fenretinide (FEN) vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group Phase III intergroup trial (EB193, INT-0151)
33. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial
34. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: Correlation with serum levels and interaction with known regulators
35. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer
36. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: Evidence for paracrine function
37. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer
38. Inhibition of normal mammary gland development and breast cancer growth by insulin-like growth factor binding protein
39. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women
40. The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer